Drugs / Inecalcitol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02802267 | Jun 2016 → Dec 2018 | acute myeloid leukemia | Hybrigenics Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT02949570 | Feb 2014 → Feb 2018 | chronic myeloid leukemia | Hybrigenics Corporation | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inecalcitol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02802267 ↗ |
| Known as | TX-522 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105107 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL2105107 ↗1“vitamin D receptor agonist” NCT02802267 ↗ |
| Modality | Small molecule | — CHEMBL2105107 ↗ |
| Route | Oral | “taken orally every other day” NCT02802267 ↗ |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL2105107 ↗ |